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Molecular Regulation of the Human IL-3 Gene:
Inducible T Cell-Restricted Expression Requires Intact
AP-1 and Elf-1 Nuclear Protein Binding Sites
By Lisa R.. Gottschalk,* Diane M. Giannola,~and
Stephen G. Emersonr
From the *Departmentof Medicine, Universityof Chicago, Illinois 60637; and the r
of Internal Medicine, University of Michigan Medical Center, Ann Arbor, Michigan 48109

Summary

he growth factor interleukin 3 (IL-3) is a major regulator of hematopoiesis. The role of IL-3 is particularly
T
interesting because IL-3 is secreted from T and NK cells and
primarily acts on both early stem cells and hematopoietic cells
committed to distinct lineages (1, 2). Alone, IL-3 stimulates
the proliferation and differentiation of bone marrow precursor
cells to produce macrophages, eosinophils, and mast cells, and
in combination with other growth factors, IL-3 influences
the development of erythrocytes, megakaryocytes, and neutrophils (3-5). In addition, IL-3 supports the growth of cell
lines derived from bone marrow cultures and enhances
1681

retrovirus-mediated gene transfer into bone marrow stem cells
(6, 7). Thus, this lymphokine forms a bridge between the
immune system and homeostasis in non-immune tissues.
IL-3 is distinguished from other growth factors by its restricted cellular expression and mode of induction. Thus, only
activated CD28 + T cells and NK cells (8-10) produce IL-3,
whereas growth factors such as GM-CSF and G-CSF are expressed in a variety of cell types (11-13). In addition, the agent
of activation is critical to optimal IL-3 gene induction in human
T cells. In contrast to other cytokines such as IL-2, TNF-c~,
lymphotoxin (LT), IFN-% and GM-CSF, incubation of T
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Interleukin 3 (IL-3) is a hematopoietic stem-cell growth and differentiation factor that is expressed
solely in activated T and NK cells. Studies to date have identified elements 5' to the IL-3 coding
sequences that regulate its transcription, but the sequences that confer T cell-specific expression
remain to be clearly defined. We have now identified DNA sequences that are required for T
cell-restricted IL-3 gene transcription. A series of transient transfections performed with human
IL-3-chloremphenicol acetyltransferase (CAT) reporter plasmids in T and non-T cells revealed
that a plasmid containing 319 bp of 5' flanking sequences was active exclusively in T cells. Deletion
analysis revealed that T cell specificity was conferred by a 49-bp fragment (bp -319 to -270)
that included a potential binding site for AP-1 transcription factors 6 bp upstream of a binding
site for Elf-l, a member of the Ets family of transcription factors. DNaseI footprint and
electrophoretic mobility shift assay analyses performed with MLA-144 T cell nuclear extracts
demonstrated that this 49-bp region contains a nuclear protein binding region that includes consensus
AP-1 and Elf-1 binding sites. In addition, extracts prepared from purified human T cells contained
proteins that bound to synthetic oligonucleotides corresponding to the AP-1 and Elf-1 binding
sites. In vitro-transcribed and -translated Elf-1 protein bound specifically to the Elf-1 site, and
Elf-1 antisera competed and super shifted nuclear protein complexes present in MLA-144 nuclear
extracts. Moreover, addition of anti-Jun family antiserum in electrophoretic mobility shift assay
reactions completely blocked formation of the AP-l-related complexes. Transient transfection
studies in MLA-144 T cells revealed that constructs containing mutations in the AP-1 site almost
completely abolished CAT activity while mutation of the Elf-1 site or the NF-IL-3 site, a previously
described nuclear protein binding site (bp -155 to -148) in the IL-3 promoter, reduced CAT
activity to <25% of the activity given by wild-type constructs. We conclude that expression
of the human IL-3 gene requires the AP-1 and Elf-1 binding sites; however, unlike other previously
characterized cytokine genes such as IL-2, the AP-1 and Elf-1 factors can bind independently
in the IL-3 gene. Thus, the exact DNA composition of these sites, flanking DNA sequences,
and the distance between the AP-1 and Ets family binding sites determine the fine specificity
of nuclear factors that bind to these sites and the resulting inducible, cell-restricted expression
of a group of lymphokine genes.
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1 Abbreviationsusedin thispaper: CAT, chloramphenicolacetyltransferase;
EMSA, electrophoretic mobility shift assay.
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quirement of AP-1 factor complex formation for NFAT
binding activity seen in the IL-2 enhancer (27), the AP-1
and Elf-1 sites in the IL-3 gene can bind their respective proteins or protein complexes independently. We also confirm
that the NF-IL-3 site is required for IL-3 gene expression.
These data provide the basis for a better understanding of
the molecular mechanisms of T cell IL-3 gene regulation and
its role in the cellular link between the immune system and
nonimmune cell proliferation.

Materials and Methods
Cells and Media. Gibbon lymphosarcoma-infectedT cells, MLA144 (ATCC TIB 201) (American Type Culture Collection, Rockville, MD) were cultured in RPMI 1640 medium (Gibco Laboratories, Grand Island, NY) supplemented with 10% FCS (Gibco
Laboratories) and 1% penicillin-streptomycin (Gibco Laboratories).
R N A I're~ration and Northem Blot A nalysi~ Totalcellular RNA
was isolated from MLA-144 cells using the guanidinium isothiocyanate~cesium chloride gradient method (31). RNA samples were
prepared from cells after incubation with one or more of the following reagents: PMA (Sigma Chemical Co., St. Louis, MO) alone
and with ionomycin (Calbiochem Corp., San Diego, CA) or with
PHA (Sigma Chemical Co.), PMA alone and finally, with media
only. After equalization by spectrophotometry and visualization
in agarose gels containing ethidium bromide, 10 #g of RNA was
fractionated on a 1% agarose/formaldehyde gel and transferred to
Hybond-N nylon filters (Amersham Corp., Arlington Heights,
IL). The filters were hybridized to a human Ib3 cDNA, which
was radiolabeled with cz-[3zP]-dCTP by random hexanucleotide
priming (32).
Isolation of Human IL3 Genomic Clone and Plasmid Construction. A genomic clone containing the human Ib3 gene and 5'
flanking sequences was isolated from a human peripheral blood
genomic library (the generous gift of John Lowe, Howard Hughes
Medical Institute, Ann Arbor, MI) by hybridization to a human
II.-3 cDNA probe. Restriction mapping of the Ib3 clone was performed using standard techniques (31).
A set of overlapping DNA sequences from the 5' flanking region of the human IL-3 were cloned in 5' to 3' orientation directly
5' of the bacterial chloramphenicol acetyltransferase (CAT) gene
in the promoterless/enhancerless vector, pCAT-Basic (Promega,
Madison, WI).
Transfections. Variouscell types were transfected with 10-20 #g
purified supercoiled plasmid DNA prepared by alkaline lysis and
cesium-chloride banding (31). The MLAq44, Clone 13, PEER,
and Jurkat cells were transfected using the DEAE-dextran method
as previously described (33). HeLa cells were transfected using 25
/~g of Lipofectin (Gibco Laboratories). 2/~g of either pRSVBGAL
or pRSVluciferase DNA was included in each transfection to correct for differences in transfection efficienciesbetween samples as
previously described (33).
CAT, ~-Galactosidas~ and Luciferase Assays. CeUswere harvested
48 h after transfection by four cyclesof freeze-thaw lysis, and protein levels were determined using a protein assay (Bio-Rad Laboratories Inc., Richmond, CA). The B-galactosidase and CAT activities were determined as previously described (33). Luciferaseassays
were performed essentially as described by De Wet (34) using luciferin substrate (Sigma Chemical Co.) and a Pharmacia luminometer (Pharmacia LKB Biotechnology Inc., Piscataway, NJ).
DNA Sequencing. DNA sequence analysis was performed on
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cells with the lectin lymphotoxin (LT) PHA alone, or with
the phorbol ester, PMA, with and without anti-CD28 fails
to induce substantial IL-3 expression (8, 14). To induce highlevel IL-3 gene expression, T cells must be activated via the
TCR/CD3 pathway or with agents that mimic this pathway
(PMA and ionomycin) (8).
Although much is known regarding the biological activities and requirements for induction oflL-3 in vitro, relatively
little is understood about the regulation of expression of this
gene. The genes for both the murine and the human homologue of IL-3 have been cloned (15, 16), and comparison between the two sequences reveals a low level of sequence identity except for some short regions of sequence homology in
the 5' and 3' flanking regions. Two recent reports have demonstrated that IL-3 m R N A accumulation is controlled at the
transcriptional and posttranscriptional levels (17, 18). The
studies describing transcriptional regulation of the IL-3 gene
have shown that the IL-3 promoter consists of two activating
regions separated by an inhibitory region (19-21). The 3' activating region contains two motifs common to many lymphokine promoters, the CK-1 and CK-2 elements (22). In
addition, the 3' activating region contains a sequence similar
to the Oct-1 motif (23, 24), NF-IL-3, and an element immediately 3' that is similar to a cAMP-responsive element
(CRE) (25). These latter two motifs, referred to as ACT-1
(21) may be important for IL-3 activation. The inhibitory
region includes a sequence referred to as NIP that binds a
nuclear protein in electrophoretic mobility shift assays
(EMSA) 1 (19) thought to restrict IL-3 expression to T cells.
However, as the NIP site also appears to be functionally inhibitory in activated MLA-144 gibbon T cells, this site alone
cannot be responsible for the restriction of IL-3 expression
to T cells.
A number of recent studies have shown that the regulatory regions of inducible T cell-related genes contain an AP-1
nuclear protein binding site in close proximity to an Ets family
nuclear protooncogene binding site, and these sites are required for inducible gene expression (26, 27). O f note, the
5' activation region of IL-3 contains a consensus binding site
for the AP-1 transcription factors. Notably, the AP-1 motif
has been shown to confer phorbol ester inducibility upon
heterologous reporter genes (28, 29) and is thought to regulate activation of many inducible genes (30). In addition, the
human IL-3 promoter contains a consensus Ets family binding
site 6 bp 3' of the AP-1 motif. Thus, given the distinct lineage restricted and TCR-inducible pattern of IL-3 gene expression, it was of interest to address the molecular mechanisms underlying the role of these sites in regulating IL-3
gene expression.
In this report, we show that the AP-1 and an Ets family
binding site, Elf-l, are required for inducible IL-3 gene expression. Moreover, the 49obp fragment containing the AP-1
and Elf-1 nuclear protein binding sites contributes to T cell-restricted expression of the IL-3 gene. In contrast to the re-
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double-stranded DNA templates using the dideoxynucleotidechain
termination protocol (35).
DNase I Footprint Analysis. A 193-bp subfragment (bp -319
to -126; sense stand) of the flanking II,3 gene was end labeled
with [c~-32p]-dGTP and [c~-32p]-TTP with the large fragment of
DNA polymerase 1 (Klenow) and isolated by PAGE. The labded
193-bp fragment was subjected to partial DNase I digestion as previously described (33), after incubation with 100-200/~g of MLA144 nuclear protein extracts. Maxam and Gilbert purine sequencing
reactions (33) were prepared and electrophoresed in parallel to the
DNase I digested subfragments.
EMSAs. Complementaryoligonucleotidescorrespondingto the
AP-1, Elf-l, NF-IL-3, and AP-1/Elf-1 nuclear protein binding sites
were synthesized with overhanging BamHI/BgllI ends and were
end labeled using Klenow as described above before EMSA:

All mutations were confirmedby DNA sequenceanalysis.The AP-1
nuclear protein binding site was changed from the wild-type sequence (TGAGTCAG) to a mutant sequence (TCTCGAGC.). The
ELF-1 nuclear protein binding site was changed from the wild type
(GGCAGGAAGC~) to a mutant sequence (TGTCTCCTTCG).
Wild-type and mutant multimerized plasmids were constructed
by multimerization of the same AP-1/Elf-1 EMSA oligonucleotide
and three additional ologonucleotides:

AP-1/Elf-I: GATCTGAGCTGAGTCAGGCTTCCCCTTCCTGCCACAGGG

AP-1/mE1F-I: GATCTGAGCTGAGTCAGGCTTCCGCAGCAGACACCAGGG

MSVLTR:TCGGAGACGGAAGCGCGC

mA~I/EI~I: GATCTGAGGTCTCGAGCGCTTCCCCTTCCTGCCACAGGG

GATCTTCCCCTTCCTGCCACAGGG

NF-Ib3:

GATCCATGGATGAATAATTA

A~I:

GATCTGAGCTGAGTCAGGCTTG

EMSAs were performed as previously described (33) except that
the binding buffer included 4% Ficoll, 10 mM Tris, 1 mM EDTA,
1 mM DTT, 75 mM KC1, and 500 ng poly (dI-dC), and the gels
were run in 0.25 x Tris-boric acid-EDTA running buffer. Unlabeled competitor oligonucleotides (50-200 ng) were included in
cold competition experiments. EMSAs included either 3-5/~g of
nuclear extracts prepared from MLA-144 cells (unstimulated and
stimulated cells), or 3 #1 of in vitro-transcribed/translated protein
or 1 #g of nuclear extract prepared from unstimulated or stimulated (10 ng/ml PMA and 400 ng/ml ionomycin for 6-8 h) normal
human T cellspurifiedby elutriation (generousgift of Drs. Lawrence
Boise and Craig Thompson, Howard Hughes Medical Institute,
Chicago, IL). The sequences of oligonucleotide competitors used
in these studies include the above probes unlabeled and:
mELF-I: GATCCCTGTGTCTCCTTCGGAA
MNIP: GATCCACCTTCTTCACTTGTTCCCA
Supershift experiments were performed in the presence of 1 #I of
rabbit or mouse antisera. These antisera were incubated with the
protein extracts for 15 rain before the addition of DNA probe in
EMSA reactions.
Preparation of Mutated Constructs. Mutations of the NF-Ib3
nuclear protein binding site were introduced by site-directed otigonucleotide-mediatedgapped-heteroduplexmutagenesisas previously
described (33) using the following synthetic oligonucleotide:
TGAGTACTAGAAAGTCATGGGACTCGAGGTACGTCTGTGGTTTTCTATGG.

The wild-type NF-IL-3site (ATGAATAA)was changed to a mutaqnt
sequence (GACTCGAG). (Underlined sequences denote regions
of mutation.) Mutations were introduced into AP-1 and Elf-1 nuclear protein binding sites using the PCR as previously described
(33) with the following oligonucleotides:
1683
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EI~I: CAGTGAGCTGAGTCAGGCTTCCGAAGGAGACACAGGGGTCCTCTCACCTGCTGC

mAFI/mEIgl:GATCTGAGGTCTCGAGCGCTTCCGCAGCAGACACCAGGG

These oligonucleotides were ligated in reverse orientation to
pSPCAT, an enhancerless plasmid under the control of the minimal SV40 promoter (36).
In Vitro Transc@tion/TranslationReactions. LinearizedcDNAs
corresponding to full-length and truncated Elf-1 cDNA (Elf110s-304; the generous gift of Jeffrey Leiden, University Chicago,
Chicago, IL) were transcribed using 10 U T7 RNA polymerase,
40 U RNasin ribonudease inhibitor (Promega) and 0.4 mM rNTPs.
Transcribed RNAs were then translated in the presence of 0.8
mCi/ml [sSS]methionine (Amersham Corp.), 40 U RNasin, 20
mM amino acids (minus methionine) and 35/~I rabbit reticulocyte
lysate (Promega). The integrity of translated proteins was assessed
by SDS-PAGE.
Antibodies. Rabbit polyclonal Elf-1 antiserum and preimmune
rabbit serum (generous gift of JeffreyLeiden), and anti-Jun family
sera that reacts with all three Jun proteins: JunB, JunE), and c-Jun
(the generous gift of Rodrigo Bravo, Bristol-MeyersSquibb Pharmaceutical Research Institute, Princeton, NY) were used in some
EMSA reactions. The Elf-1 antiserum does not react with Ets-1
or Ets-2. Anti-IL2 receptor (IL-2R; Becton Dickinson, Mountainview, CA) mouse mAb was used in control reactions.

Results
Isolation and Characterization of a Genomic Clone Containing
the Human 11.-3 Gene. We isolated a clone containing the
full-length IL-3 gene from a human genomic library with
a human IL-3 cDNA as a probe and standard techniques. This
clone includes 3 kb of 5' flanking sequence and 5 kb of 3'
flanking sequence. To identify regulatory elements in the 5'
flanking region, we sequenced 1,400 bp of DNA 5' of the
transcriptional start site (Fig. 1). A computer homology search
of the human IL-3 DNA sequence revealed similarities to
potential regulatory motifs not previously observed. These
include an ets-1 family nuclear protooncogene binding site
(EBS) with one mismatch (bp - 288 to - 278; antisense strand;
GGCAGGAAGGG) (37-40), Of note, this EBS contains an
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-319

-270

-175

-150

AGGCCCAGTTGAAACCAGGGAGTTGCTCTCCTTTCTCCTCCCTTGACCTCACCC~TCAGACCATGCCAATTC
TGCCTCCTAAACCTCCCAGGCCAGCCCCTCCCCCAGCTCCCAGTGACAGTGTCCTCAGGTACCTGAGCTCAG
-660
NIP
CTCTCGGTGCTACCAGAGGGACTGCAGGGCTGCAGAGGCTGAGTCCCACACGCAGGG~C42C.~T~CACT
GCTAGCAGACCAGTAAGAGAATGGCCACCTGGGGCCTGAGCGCCCTCGGCCATCCACCAGAAACAAAGTGTC

Cell LJne Activation

8s0.5

Jurkat

AAGGAGAAGCTGCCCGAAGCCCATGGGACAAACCACTGGGGACTGGAACACCAGTAATTCTGTATTGGGAAG

-150CAT

+

128,2

-175CAT

-270CAT

-319CAT

4,0.6

1,0.4

4,1
37,10

88,14

2,0.7

1

1

1

+

21, 2

65,27

1

+

86,32

3

1

2 , 0.7

+

18,3

16,4

1

2,0.3

25,1

13, 4

1

CGGCACCAAGAGATGTGCTTCTCAGAGCCTGAGGCTGAACGTGGATGTTTAGCAGCGTGACCGGCTACCAGA

PEER
CAAACTCTCATCTGTTCCAGTGGCCTCCTGGCCACCCACCAGGACCAAGCAGGGCGGGCAGCAGAGGGCCAG
-317
AP-I
GGTAGTCCAGGTGATGGCAGATGAGATCCCACTGGGCAGGAGGCCTCAGTGAGC~k'~G~k~AGGCTTCCCCTT
Elf-i
-270
NIP
EBS
~ACAGGGGTCCTCTCACCT~TTCCCATCTCTCATCCTCCTTGACAAGATGAAGTGATA
NFIL-3 "CRE"
-i75
(ACT-IB) (ACT-IA)
CCGTTTAAGTAATCTTTTTTCTTGTTTCACTGATCTTGAGTACTAGAAAGTCATGCd~TGA~TAATT&C~.TCT
CK-I/CD28R CK-2/GATA3
EBS
CACC
Spl
GTGGTTTTCTAT~GATCCTTCCGACGCCTGCCCCACACCACCACCTCCCCCG
1
CCTTGCCCC~GGTTGTGGGCACCTTGCTGCTGCACATATAAGGCGGGAGCTGTTGCCAACTCTTCAGAGCCC
Start ofl
CACGAAGGACCAGAACAAGACAGAGTGCCTCCTGCCGATCCAAACATGAGCCGCC
Transcription
l
Coding sequences

B.
AA
AGGAGGATGTG
GACC
CAA
-277: 5' GGCAGGAAG~G
EBS:

3'

Figure 1. DNA sequence analysis of the upstream region of the human
IL-3 gene. The nudeotide sequence of the I1,3 gene from -855 to the
start of coding sequences is depicted. Sequences similar to known nuclear
protein binding sites and those defined in the I1,3 gene are underlined
and identified. The consensus sequencesfor the AP-1 and ets family binding
sites (EBS), and comparison to sequences in the 11,3 gene are shown in
B. The single divergent base is underlined. These sequence data are available from EMBL/GenBank/DDBJ under accession number L10616.

A at nucleotide 8, which has been shown to permit binding
to the Elf-1 transcription factor (41). Two additional EBS
are present in the IL-3 5' flanking sequences (-108 to -98;
-230 to -220), in addition to a CD28-responsive element
(CD28R; bp -126 to -116; GAGGTTCCATG) (42). The
finding of a CD28-responsive element is of interest because
earlier studies in this laboratory demonstrated that IL-3 gene
expression is limited to the CD28 + T cell subpopulation (8).
Contained within the lymphokine CK-2 motif is a consensus
sequence for the GATA-3 transcription factor (AGATAA) (43),
and this site is conserved within murine IL-3 gene sequences.
Finally, a site similar in 8 of 10 bp to the NIP inhibitory
motif (19) is located 657 bp upstream of the transcriptional
start site.

Identificationof cis-Acting Transc@tionalRegulatorySequences
that May Be Involved in T Cell-Restricted IL-3 Gene Expression. In an effort to define transcriptional regulatory elements
that modulate IL-3 gene expression, we examined a series
of heterologous reporter constructs containing the bacterial
CAT gene and human genomic IL-3 subfragments in various cell lines. Initially, a set of contiguous D N A segments
from the 5' flanking region of the IL-3 gene was cloned in
5' to 3' orientation directly 5' of the CAT gene in the promoterless/enhancerless vector, pCAT-basic. As shown in Fig. 2, constructs containing 150 bp (which includes the CK-1, CK-2,
and CRE elements) and 175 bp (which includes the CK-1,
1684

5,0.8

Clone 13

HeLa

8,0.3

12,8
115,41

1,0.5
3,1

10,4
158,62

1

Figure 2. Transcriptional activity of CAT constructs containing 5'
flanking region DNA segments of the human I1,3 gene in various cell
lines. II.~3-CATconstructs containing 150-319 bp of 5' flanking DNA
sequences of the human Ib3 gene with 30 bp of 5' untranslated DNA
cloned into pCAT were transiently transfected into Jurkat, PEER, and
MLA-144 T cells, into Clone 13 B cells, and into HeLa fibroblasts, along
with an efficiency plasmid, pRSV3gal or pRSVluciferase, and tested for
transcriptional activity. Some of the nuclear protein binding sites that these
constructs included are shown at top. Following transfection, the cells
were divided into two groups: the first was maintained in media only while
the second was induced with activation agents known to elicit 11,3. The
activation agents (denoted by +) used in Jurkat, PEER, and Clone 13
cells were PMA (5 ng/ml) and ionomycin (400 ng/ml), and those used
in MLA-144 cells were PHA (2/zg/ml) and PMA (5 ng/ml). The various
cell lines were induced for 6-8 h before the harvest of extracts, and these
extracts, normalized for transfection efficiencies,were used in CAT assays
as previously described. Relative CAT activity is shown in the table (mean
and SD) and represents the activity given by a particular construct compared to the activity given by the pCAT vector alone. Each construct was
tested four times in Jurkat, PEER, and MLA-144cells, three times in Clone
13 cells and twice in HeLa cells with different plasmid preparations.

CK-2, CRE, and NF-II.-3 elements) of 5' flanking sequence
(with 30 bp of 5' untranslated sequences) increased CAT activity after activation in all cell lines tested. CAT activity was
also observed in transfected HeLa cells and lower level activity was demonstrated in unstimulated T and B cells. In
contrast, a construct containing 319 bp of 5' flanking sequence
was active exclusively in T cells. Deletion analysis demonstrated that this activity was lost in T cells when 49 bp was
removed from the 319-bp construct, and this construct was
also inactive in non-T cell lines. The 49-bp DNA segment
(bp -319 to -270) contains a consensus AP-1 nuclear protein binding site (bp -301 to -295) 6 bp 5' to the Elf-1
nuclear protein binding site described above. Such an AP1/Ets family member nuclear protein binding cassette has been
implicated in the activation of other cytokine genes (26, 27).
Although -270CAT included the putative silencer NIP,
mutation of the NIP site from GCTC~CATGC to TCTTCACTTG in the context of -270CAT failed to increase CAT
activity in MLA-144 T cells or in Clone 13 B ceils to the
level demonstrated by - 175CAT (data not shown). This suggests that additional DNA sequence is necessary for full activity in T cells regardless of the status of NIP site integrity,
or that the low-level activity given by -270CAT is not en-
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A
TGACTCA
G
TRE:
TGAGTCAG
-301: 5' TGAGTCAG 3'

AP-I:

MLA-144

1
119,39
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tirely due to the NIP site. Together, these data provide evidence that the 49-bp fragment is required for the T cell-restricted pattern of IL-3 gene expression and that it may
function in concert with other negative regulatory elements
within the IL-3 promoter.

Activation of MLA-144 Cells Induces High-level IL-3 Gene
Transcripts and Nuclear Proteins that Bind to DNA Sequences
within the 49-bp Fragment in the 5' Flanking Sequences of the
IL-3 Gene. To study further the role of the 49-bp fragment

MLA-144 Cells Contain Multiple SpecificNuclear Proteins that
Bind to DNA Sequences in the IL-3 Promoter. To determine
the number and the specificity of nuclear proteins that bind
to the protected sequences present in the 49-bp IL-3 gene
subfragment, we performed a series of EMSAs with MLA144 nuclear extracts and double-stranded synthetic oligonucleotides corresponding to the AP-1 and Elf-1 nuclear protein binding sites. Fig. 4 A shows that when nuclear extracts
from resting MLA-144 cells were tested with the AP-1/EIf1 DNA probe (including intervening DNA), four lowmobility bands (arrows) bound specifically, as demonstrated
by competition with wild-type oligonucleotides (lane 2) but
not by unrelated DNA competitor (MNIP, lane 6) or a mutant Elf-1 DNA competitor (lane 4). Specific bands were also
demonstrated using stimulated MLA-144 extracts; however,
with the exception of the lowest mobility band, the bands
were diffacult to distinguish. Of note, the highest mobility
bands do not appear to be specific because they are present
despite the addition of wild-type DNA competitors. Further
cold competition experiments revealed that an oligonucleotide corresponding to a consensus AP-1 nuclear protein binding
site competed the middle complexes in both unstimulated
and stimulated nuclear extracts (lanes 5 and II). In contrast,

Figure 3. Northern blot analysis of MLA-144RNA
and DNase I footprint analysisof the 5' flanking region
of the human Ib3 gene. (.4) Northern blot analysisof
human II.,3 expressionin MLA-144cells during activation. Total cellular RNA was prepared from MLA-144
cells incubated for 8 h with either media alone, or with
PMA (5 ng/ml) and ionomycin(400ng/ml), or with PMA
(5 ng/ml) and PHA (2/~g/ml), or with PMA (100ng/ml)
alone or with PHA (2/zg/ml) alone. Ten/,g of RNA
from each condition was equalized for 28S and 18S
ribosomal tLNA, fractionatedby gel dectrophoresis, and
transferred to nylon. The nylon filter was hybridized to
a radiolabeledhuman II.,3 DNA probe and later hybridized to a human B-actin DNA probe and the resulting
autoradiograms are shown. (B) DNase I footprint anal)'sis of the 5' flanking sequencesof the human Ib3 gene.
A 193-bpfragment (bp - 319 to - 126; sensestrand) was
end labeledand incubatedwith unstimuhted (uns)or with
stimulated (stira)or without (Contro~MLA-144nudear
extract before partial digestion with DNase I. Standard
Maxam and Gilbert purine (G + A) sequencingreactions
of the same fragment were prepared and run in parallel.
The protectedDNA segmentthat includesAP-1and Elf-1
nuclear protein binding sites is marked with brackets in
B and boxedwithin the DNA sequencein C. The AP-1
and Elf-1nuclearproteinbinding sitesare underlinedin C.
1685
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in IL-3 gene transcription, it was necessary to identify cells
that could be induced to express high levels of IL-3. Northern
blot analysis of tLNA obtained from Jurkat and PEER T cells
revealed that these cells produced extremely low levels of IL-3
gene transcripts (data not shown). However, as shown in Fig.
3 A, MLA-144 cells can be induced by incubation for 8 h
with PMA (5 ng/ml) and PHA (2/~g/ml) to produce high
levels of IL-3 gene transcripts and to a lesser degree after incubation with PMA (5 ng/ml) and ionomycin (400 ng/ml)
or with PMA (100 ng/ml) alone. These levels were comparable
with levels of IL-3 expression obtained in primary human
T cells (L. Gottschalk, unpublished results). Notably, no IL-3
gene transcription was detected in R.NA prepared from cells
incubated with media alone.
These data confirm that, unlike other inducible cytokine
genes, IL-3 gene expression is not induced with PHA alone
(8) and suggest that relatively unique molecular mechanisms
may regulate IL-3 gene transcription. To identify nuclear protein binding sites within the 49-bp subfragment of the human
IL-3 gene promoter that conferred T cell specificity in CAT
assay studies, we subjected a 193-bp DNA subfragment (bp
-319 to -126; sense strand) containing the 49-bp segment
(bp -319 to -270) to DNaseI footprint analysis. Fig. 3, B

and C shows that nuclear extracts prepared from MLA-144
cells protected the AP-1 site, Elf-1 site, and intervening DNA
from digestion by DNaseI (bracketed and boxed) and that
no other regions in the 49-bp segment within the 193-bp
fragment bound nuclear proteins. Because these sites were
protected by nuclear extracts prepared from both unstimulated and stimulated MLA-144 cells, further characterization
of the proteins that interact with the IL-3 gene DNA was
performed by EMSAs.
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in vitro, the truncated version was used in competition experiments. As seen in Fig. 5, the AP-1/EIf-1 DNA probe
bound truncated Elf-1 (t-Elf-l, lane 2). This binding activity
was abolished by the addition of unlabeled wild-type Elf-1
competitor (lanes 3 and 4) but was still present when
nonspecific DNA competitor was added (lane 5). As expected,
no binding activity was observed when in vitro translation
reactions without transcribed RNA was used in EMSAs (lanes
1 and 6). Finally, a control probe that contains an Elf-1 nuclear protein binding site from the MSV LTK (MS V) bound
the in vitro-transcribed and translated tell-1 protein (lane
7). These EMSA data demonstrate that Elf-1 protein can bind
directly to DNA sequences in the IL-3 promoter.

competition with an oligonucleotide that corresponds to the
Elf-1 site alone showed that the lowest mobility specific band
is competed when mixed with the AP-1/EIf-1 probe and both
stimulated and unstimulated extracts. In addition, when an
Elf-1 DNA competitor is added in EMSA at the same time
with AP-1 DNA competitor, the lower predominant band
evident in lanes 5 and 11 (AP-1 DNA competitor alone) is
reduced suggesting that there are two bands that run with
similar mobility, one binding to the AP-1 site and one binding
to the Elfol site (data not shown). Together, the EMSAs demonstrate specific and distinct complex formation with the
AP-1/Elf-1 oligonucleotide probe and proteins from both unstimulated and stimulated MLA-144 cells.
Fig. 4 B shows that an oligonucleotide corresponding to
the AP-1 binding site in the IL-3 gene specifically bound nuclear proteins from stimulated MLA-144 cells in the absence
of the Elf-1 site (lanes 1, 3, and 4). However, comparison
of the complexes formed with the AP-1/EIf-1 probe described
above to those formed with the AP-1 probe alone (Fig. 4
B) and the Elf-1 probe alone (see Fig. 6, lane 5) demonstrate
that at least some of the binding activity observed with the
AP-1/Elf-1 probe may require cooperative binding of AP-1
and Elf-1 or of yet undefined transcription factors. Of note,
the addition of unlabeled NF-IL-3 competitor eliminated all
complex formation observed with a labeled AP-1 consensus
probe (Fig. 4 B, lane 2) and stimulated extracts, suggesting
that the NF-IL-3 nuclear protein binding site may bind AP-1
transcription factors.

tify the proteins within MLA-144 nuclear extracts that bind
to IL-3 promoter DNA sequences, we performed EMSAs as
above with anti-Jun and anti-Elf-1 antisera. Fig. 6 shows
that addition of anti-Jun family serum which recognizes JunB,
Jun.D, and c-Jun blocked the formation of the middle complexes with both unstimulated and stimulated MLA-144 nuclear extracts (compare lanes I and 8 with 3 and I0). As described above, the same bands were blocked by addition of
consensus AP-1 DNA competitor. When specific anti-Elf-1
serum was added into the EMSA reactions, it was difficult
to demonstrate the disappearance of a band using the AP-1/
Elf-1 DNA probe (lane 2); however, the higher mobility band
(closedarrow) formation was blocked in EMSA reactions containing the shorter Elf-1 DNA probe (f-ELF-I; compare lanes
5 and 6). This lower band ran with the same mobility as

The AP-1/EIf-1 DNA ProbeBinds In Vitro Transcribed/TranslatedElf-1 Proteinand ls Competed by Anti-Elf-I Sera. To test
whether Elf-1 protein binds to the EBS in the IL-3 promoter,
truncated and full-length in vitro-transcribed/translated Elf-1
protein was used in EMSAs with the AP-1/Elf-1 DNA probe.
Because truncated Elf-1 protein (Elf-ll0s-3o4) binds with
equivalent specificity as full-length Elf-1 protein (44) and because of higher translation efficiency of smaller transcripts
1686

Figure 5. EMSAwith either a radiolabeledAP-1/Elf-1probe or MSV
probe and in vitro-transcribed/translated truncated Elf-1(t-Elf-l) or translation products prepared without KNA (-). Lanes in which unlabeled
oligonucleotide competitor was added and the amounts used are noted.
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Figure 4. EMSAanalysesof the AP-1/Elf-1nuclearproteinbinding sites
in the human I1.-3gene. (A) EMSAusing a radiolabeledAP-1/EIf-1DNA
probe and nuclear extracts from unstimulated or PMA/PHA-stimulated
MLA-144cellsin the presenceof 200 ng of unlabeleddouble-strandedoligonucleotide competitors as marked. (B) EMSA analysesusing radiolabeled AP-1 as a probe with stimulated MLA-144nuclear extracts. Unlabeled competitor oligonucleotides (200 ng) were used as marked.

Addition of Elf-1 andJun Antisera Block Complex Formation
in EMSA Reactions with MLA-144 NuclearExtracts. To iden-
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the band observed in EMSA reactions containing in vitrotranslated full-length Elf-1 protein and the AP-1/Elf-1 probe
(data not shown). In addition, a faint supershifted complex
(open arrow) was observed in reactions containing either DNA
probe with unstimulated MLA-144 nuclear extracts (lanes
2 and 6), and in reactions with the AP-1/EIf-1 probe and
stimulated extracts (compare lanes 10 and 11). The addition
of IL-2R antibody or preimmune serum did not alter the
binding activities observed with either probe or with either
nuclear extract (lanes 1, 4, 5, 7, and 9). Interestingly, the
specific band with the lowest mobility observed with both
probes (lanes 2 and 6) was unaffected by addition of the Elf-1
antiserum. However, the binding activity appeared to be
greater in the absence of the AP-1 nuclear protein binding
site (with Elf-1 probe). This band was also present when nuclear extracts prepared from PEER and Jurkat T cells, and
Clone 13 B cells were used (data not shown). In summary,
these EMSA data demonstrate that MLA-144 T cells contain
proteins that bind specifically to AP-1 and Elf-1 nucleotide
sequences, that Elf-1 protein binds to the Elf-1 nucleotide
sequences in vitro, and that Elf-1 and Jun antisera block proteins or protein complexes within MLA-144 nuclear extracts
that bind to these two sites.

Intact AP-1 and Elf1 Nuclear Protein Binding Sites Are Required for Full Functional Activity. We next asked whether
1687
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Human T Cells Contain Multiple Inducible Specific Nuclear
Proteins That Bind to D N A Sequences in the IL-3 Promot~ To
investigate the interaction of human T cell nuclear proteins
with the 49-bp IL-3 promoter sequence, we performed EMSAs
using various oligonucleotide probes and nuclear extracts prepared from uninduced and induced, purified human T cells.
Before extract preparation, a portion of the human T cells
was stimulated for 6-8 h with PMA and ionomycin, which
induces high levels of IL-3 transcripts (data not shown). Fig.
8 A shows that multiple complexes were formed with induced T cell extracts and both the AP-1/EIf-1 (lane 2, arrows)
and the AP-1 DNA probes (lane 4, arrows). In contrast to
EMSA analysis performed using nuclear extracts from unstimulated MLA-144 cells, very little complex formation is
evident using uninduced human T cell extracts (lanes 1 and
3). However, consistent with results obtained with nuclear
extracts prepared from MLA-144 cells, the band pattern seen
with human T cell extracts and the AP-1/Elf-1 probe (lane
2) compared with the pattern observed with these extracts
and the AP-1 probe (lane 4) is distinct, with fewer and less
intense complexes formed with the AP-1 probe.
The specificity of nuclear protein binding of induced T
cell nuclear proteins to the AP-1/Elf-1 DNA subfragment
was assessed using unlabeled DNA competitors, as shown
in Fig. 8 B. The two higher mobility bands denoted by dosed
arrows were specific as demonstrated by competition with
wild-type competitor (lane 2) but not by unrelated competitor (MNIP, lane 5) or mutated competitor (MEIfl, lane 6).
Clearly, the lowest mobility band denoted by a dosed arrow
is nonspecific because it is competed by both specific and
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Figure 6. EMSAusing radiolabeledAP-1/EIf-1, Elf-l, or MSV oligonucleotideprobeswith unstimulatedor stimulatedMLA-144nuclear protein extractsin the presenceof various antisera. Variousantisera, as noted,
were incubated with the nuclear proteins for 15 min before the addition
of the radiolabeledprobe. Lanes I-7 wererun on one gel while lanes 8-II
were run on a separategel. The complexcorrespondingto full-length Elf-1
(f-Elf-I)is denotedby a closedarrow as well as the supershiftedcomplexes
(openarrows)evident in lanes 2, 6, and 11. Preimmune sera and anti-IIr
receptor (c~-Ib2R) were used as controls.

the NF-IL-3, AP-1, and Elf-1 sites that bound nuclear proteins played important functional roles in IL-3 gene transcriptional activation in intact MLA-144 cells. A series of mutant
IL-3 promoter constructs were produced and tested for transcriptional activity after transfection into MLA-144 cells. Mutations were introduced into the -319-bp promoter in the
AP-1, the Elf-l, the NF-IL-3 nuclear protein binding sites
or in a combination of sites (changes noted in Materials and
Methods and in the figure legend). In addition, constructs
containing multimerized oligonucleotides corresponding to
the wild-type and mutant AP-1 and Elf-1 sites with intervening nucleotides were cloned into a vector under the direction of the minimal SV40 promoter and tested for transcriptional activity. Fig. 7, A and B shows that the AP-1 and the
Elf-1 nuclear protein binding sites were necessary for full activity in stimulated MLA-144 cells both in the context of
the endogenous IL-3 promoter (Fig. 7 A) and in constructs
containing the multimerized DNA segments controlled by
the minimal SV40 promoter (Fig. 7 B). Finally, mutation
of the NF-IL-3 site in -319CAT reduced CAT activity by
80%, demonstrating a role for this site as well. Interestingly,
the reduced CAT activity produced by -319CAT with the
NF-IL-3 mutation in comparison to that produced by the
wild-type construct is less dramatic when transfected into
Jurkat T cells (data not shown). The studies detailed above
demonstrate the requirement of intact AP-1, Elf-1, and NF o
IL-3 nuclear protein binding sites for inducible IL-3 gene expression.
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nonspecific competitors. The competitions observed using
unlabded AP-1 and Elf-1 D N A probes are consistent with
the pattern seen with MLA-144 nuclear extracts because (a)
at least one complex is evident in the presence of competitor
AP-1 oligonudeotide (lane 3, open arrow) and this band runs
1688

with similar mobility to the band formed with the same probe
and in vitro-translated full-length Elf-1 (lane 7); and (b) it
is difficult to demonstrate diminution of the highest mobility
band denoted by a dosed arrow in the presence of Elf-1 D N A
competitor (lane 4), suggesting that there are two bands that
run with similar mobility. Finally, the lowest mobility specific
band observed in EMSA reactions with the MLA-144 nuclear extracts does not appear to be present in EMSA reactions conducted with human T cell nuclear extracts.

Discussion
IL-3 is a potent inducible hematopoietic growth factor that
is produced solely by activated T and N K cells. In this report, we demonstrated that multiple nuclear protein binding
sites are required for T cell-restricted expression of the human
IL-3 gene, including sites that bind to AP-1 transcription
factors and to Elf-l, an Ets family transcription factor. W i t h
oligonucleotides corresponding to the AP-1 and Elf-1 binding
sites, we have shown by direct binding and competition that
these sites, in fact, bind AP-1 and Elf-1 transcription factors.
In the absence of a D N A subfragment containing the AP-1
and Elf-1 binding sites, CAT constructs including a segment
of the IL-3 promoter/enhancer were active in both T and
non-T cells. In addition, mutation of an element thought
to be involved in restricting IL-3 expression, NIP, failed to
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Figure 7. Functional analysis of three nuclear protein binding sites in
the human Ib3 gene. MLA-144cells were transfected with a CAT construct under the control of 319 bp of the human IL-3gene promoter (A)
or with a CAT construct containing three copies of the AP-1/Elf-1 nuclear protein binding sites found in human II:3 under the control of the
minimal SV40 promoter (B). CAT constructs with mutations in up to
three of the nuclear protein binding sites were also tested. In addition,
2/~g of pKSV/~galwas included in each transfection to normalize efficiendes. After transfection, the cells were divided into two groups: one that
received PMA (5 ng/ml) and PHA (2/~g/ml) 8 h before harvest and a
second group that was incubated with media only. CAT assayswere performed as previouslydescribed (33). (A) Activity of constructs containing
mutated nuclear protein binding sites in the context of the endogenous
II.-3promoter. The mutations were (AP-1)TGAGTCAGto TCTCGAGC,
(Elf-l) GGCAGGAAGGGto TGTCTCCTTCG, and (NF-Ib3) ATGAATAA to GACTCGAG.Activity shown is that of stimulated MLA-144cells
only. Relative CAT activity is that given each construct compared to the
activity given by the pCAT vector alone. Each construct was transfected
at least three times and the data shown are from a representative experiment. (B) Activity of intact and mutant multimerized AP-1/Elf-1 nuclear
protein binding sites in constructs under the control of the heterologous
minimal SV40 promoter. The mutations introduced into the AP-1 site
were identical to A. The Elf-1 site in this construct was mutated to
TGTCTGCTGCC. Cultures stimulated with PHA/PMA are denoted by
(+). Relative CAT activity here represents the activity given by the individual construct in extracts from induced cultures compared to the activity given by the construct in extracts from uninduced cultures. The
uninduced and induced samples were assayed on the same day but run
on two thin layerchromatographicplates. Each construct was transfected
three times with different preparations of plasmid DNA and the data
presented are representative of one experiment.

Figure 8. EMSAusing radiolabeledAP-1/Elf-1 and AP-1 oligonucleotide probes with nuclear protein extracts prepared from unstimulated and
stimulated human T cells purified by elutriation. (A) EMSAusing radiolabeled AP-1/Elf-1 or AP-1 DNA probes with unstimulated and stimulated human T cell nuclear extracts. Complexes formed by nuclear proteins and the AP-1/Elf-1 probe are denoted by dosed arrows, whereas
complexes formed by nuclear proteins and the AP-1 probe are denoted
by open arrows. The panels depicting analyses with the AP-1/Elf-1 probe
and the AP-1probe represent gels exposedto film for identical timepoints.
(B) EMSAusing a radiolabeledAP-1/Elf-1probe and nuclear extracts from
stimulated human T cells in the presence of 200 ng of unlabeled doublestranded oligonucleotide competitors as marked.
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(27) have shown that NFAT complex formation requires
cooperation between an Ets family factor and AP-1 dimers,
and the EBS and AP-1 binding sites in the NFAT motif are
1 bp apart. Likewise, Wasylyk et al. (26) demonstrate that
the ets-1 protein interacts with AP-1 dimers to activate transcription through the PEA3 motif in the polyoma enhancer.
In the oncogene-responsive domain of the polyoma enhancer,
the ets-1 and AP-1 sites overlap by severalbases, and analyses
using chimeric constructs revealed that maximal levels of activity were possible only when these sites were adjacent (48).
In contrast, the Elf-1 and AP-1 nuclear protein binding sites
in the IL-3 gene are separated by six nucleotides, and the
resulting spatial orientation may account for the observation
that these sites can bind to some proteins or protein complexes independently.
Although we have demonstrated the critical importance
of the AP-1 and Elf-1 sequences to inducible, T cell-restricted
IL-3 gene expression, both AP-1 and Elf-1 transcription factors
themselvesare found in non-T cells as well as in T cells. Therefore, the manner in which AP-1 and Elf-1 binding proteins
might confer T cell IL-3 specificity is of extreme interest including severalpossibilities. First, T cell-specific proteins may
interact with the AP-1 or Elf-1 binding factorsbut not directly
with DNA. Second, there may be yet undefined regulatory
protein binding sites and binding factors not detected by
DNaseI and EMSA analyses. Finally, the AP-1 and Elf-1 transcription factors may undergo posttranslational modification
in vivo leading to T cell-restricted gene expression.
Previous investigators have suggested that two different
nuclear protein binding sites, the NF-IL-3 and the NIP sites,
may play roles in T cell-specific IL-3 gene expression. For
example, Davies et al. (21) implicated the NF-IL-3 site (within
the ACT-1 motif) in IL-3 expression, yet the effect of a mutation in this site is only evident in the context of a construct
truncated just 5' to the NF-IL-3 site. Within a larger construct (300 bp of 5' flanking DNA), the effect of an ACT-1
mutation is negligible (21). In contrast, our data show that
mutation of the NF-IL-3 site within the context of 319 bp
of 5' flanking sequence dramatically reduces CAT activity as
compared to that of the native IL-3 promoter. There are several possibilities for this discrepancy. First, the designs of mutant constructs were different. We mutated specific bases
within the NF-IL-3 site, whereas Davies replaced the entire
NF-IL-3 site and the 3' CRE element with a short DNA
spacer (15 to 6 bp). Thus, in the latter construct the spatial
interactions were dramatically altered and the NF-IL-3 site
mutations were not isolated. In fact, when we tested a construct truncated immediately 3' of the NF-IL-3 site, -150CAT
(including the CRE or 3' section of ACT-l), this construct
gave 50-100% of the activity given by the larger -175CAT
construct. Thus, Davies' deletion of the CRE site would be
expected to impact greatly on transcriptional activity. Second,
the modes of IL-3 gene induction in the transfected MLA144 cells were different. We induced IL-3 gene expression
in MLA-144 cells with PHA and PMA, whereas Davies et
al. activated these cells with PMA alone. Our Northern blot
analysis shows that IL-3 transcripts in MLA-144 cells are
significantly lower following incubation with PMA in con-
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increase transcription to the level seen with a smaller subfragment when transfected into activated T and non-T cells.
Together, these data support the conclusion that the AP-1/
Elf-1 cassette is critical to cell-restricted and inducible IL-3
gene expression.
The AP-1 and Elf-1 binding sites were found to be absolutely required for IL-3 gene expression, because constructs
with these sites deletedwere inactivein induced T cells. DNaseI
footprint and EMSA analysesrevealedthat the AP-1 and Elf-1
binding sites as well as intervening DNA bound multiple
specific nuclear protein complexes, and there were differences
in the mobilities but not the intensities of the complexes observed in EMSAs using extracts from resting or induced MLA144 cells. These results suggest that there may be distinct
nudear proteins that bind to the IL-3 promoter in induced
and uninduced extracts, or that one or more of these proteins might undergo posttranslational modifications after activation, or that different protein-protein interactions may
exist in resting and induced cells. Further studies with antisera revealed that both Elf-1 and Jun family binding proteins individually formed complexes with the AP-1/Elf-1
DNA probe. The presence of proteins that were blocked by
Jun family antiserum in extracts from resting MLA-144 cells
may be attributed to constitutive expression of Jun and Fos
family proteins in these cells. Evidence for high constitutive
expression ofJunD, and low but detectableexpressionofJun-B,
c-Jun, and Fra-1 has been demonstrated in other resting cells
(45, 46). Alternatively, distinct combinations of Jun and Fos
proteins may bind to the IL-3 gene during different stages
of activation (47). Because it is evident that protein-protein
interactions between the various Jun and Fos transcription
factors mediate the differential effects observed in regulation
of AP-1 proteins (30), examination of the individual constituents of the Fos/Jun or Jun/Jun complexes binding to the
IL-3 gene AP-1 site in uninduced or induced MLA-144 T
cells will be important to elucidate. Finally, EMSA studies
using purified human T cells demonstrated that binding activities were largely limited to extracts prepared from induced
cells. This result is not unexpected, and the demonstration
of binding activities in unstimulated MLA-144 cell extracts
possibly reflects the transformed state of the MLA-144 cells.
The exact DNA composition of the AP-1 and Ets family
nuclear protein binding sites, flanking DNA sequences, and
the distance between these sites may determine the fine
specificity of nuclear factors that bind to these sites. Members
of the Ets protooncogene family encode transcription factors
that bind to purine-rich DNA sequences present in the
promoters and enhancers of several cellular and viral genes
(26, 33, 38, 40, 49, 50). The core GGA sequences are absolutely required for DNA-protein interaction, whereas the
flanking sequences determine the specificity of DNA binding
by the different Ets family members (39). With respect to
the IL-3 gene, examination of the EBS sequence predicts that
the IL-3 gene can bind Elf-1 because of a permissive A at
nucleotide 8 (41). Whether an Ets family transcriptional protein actually forms a complex with AP-1 dimers or a third
protein bridge may depend on the distance separating the
two nuclear protein binding sites. For example, Boise et al.
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deficiency after bone marrow transplantation. Schwartz and
Kong et al. (51, 52) have found that antigen-specific anergic
T cell clones display profound deficiencies in the binding of
AP-1 transcription factors to AP-1 nuclear protein binding
sites. Similar AP-1 nuclear protein deficiencies could well explain the T cell anergy routinely observed following bone
marrow transplantation in which T cells arising after transplant fail to secrete either IL-3 or GM-CSF in response to
mitogens (53, 54). Thus, T cell activation via AP-1 and EBS
nuclear binding proteins may be a major molecular checkpoint in the expression of the developmental program of T
cells in diverse clinical settings.
In summary, these data indicate that 5' flanking sequences
containing nonadjacent AP-1 and Elf-1 nuclear protein binding
sites play a major role in conferring T cell specificity to IL-3
gene expression. In contrast to the NF-IL-3 and NIP sites,
the effects of the AP-1 and Elf-1 binding sites in reporter
constructs with 5' flanking IL-3 gene sequences distinguish
T cells from non-T cells and are most evident under conditions of T cell activation that maximally stimulate IL-3 production per se. Future studies identifying the particular members
of the Jun family, as well as additional proteins involved in
activation at the AP-1 and Elf-1 sites will be extremely interestingly in illuminating the molecular basis of the specificity
of T cell cytokine gene expression.
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